SF3B1 mutations were detected in 428/4580 (9.3%) cases and were the most frequent mutation in M-CLL (148/2454, 6.0%), advanced-stage patients at diagnosis (206/1212, 17.0%) and patients requiring treatment (368/2680, 13.7%). Here, SF3B1 is linked to B-cell chronic lymphocytic leukemia.